XTX Topco Ltd Makes New Investment in C4 Therapeutics, Inc. (NASDAQ:CCCC)

XTX Topco Ltd acquired a new position in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 40,100 shares of the company’s stock, valued at approximately $64,000. XTX Topco Ltd owned approximately 0.06% of C4 Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Invesco Ltd. grew its position in C4 Therapeutics by 7.2% during the 4th quarter. Invesco Ltd. now owns 69,193 shares of the company’s stock worth $249,000 after purchasing an additional 4,647 shares in the last quarter. Northern Trust Corp grew its position in C4 Therapeutics by 1.1% during the 4th quarter. Northern Trust Corp now owns 495,043 shares of the company’s stock worth $1,782,000 after purchasing an additional 5,223 shares in the last quarter. Cubist Systematic Strategies LLC grew its position in C4 Therapeutics by 6.6% during the 4th quarter. Cubist Systematic Strategies LLC now owns 109,825 shares of the company’s stock worth $395,000 after purchasing an additional 6,799 shares in the last quarter. JPMorgan Chase & Co. grew its position in C4 Therapeutics by 29.6% during the 4th quarter. JPMorgan Chase & Co. now owns 33,409 shares of the company’s stock worth $120,000 after purchasing an additional 7,630 shares in the last quarter. Finally, LPL Financial LLC grew its position in C4 Therapeutics by 13.1% during the 4th quarter. LPL Financial LLC now owns 70,325 shares of the company’s stock worth $253,000 after purchasing an additional 8,150 shares in the last quarter. 78.81% of the stock is currently owned by hedge funds and other institutional investors.

C4 Therapeutics Price Performance

Shares of NASDAQ CCCC opened at $2.46 on Friday. C4 Therapeutics, Inc. has a one year low of $1.09 and a one year high of $7.22. The business’s 50-day moving average price is $1.92 and its two-hundred day moving average price is $1.97. The company has a market capitalization of $175.08 million, a P/E ratio of -1.56 and a beta of 2.97.

C4 Therapeutics (NASDAQ:CCCC) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.01. The business had revenue of $6.46 million during the quarter, compared to analysts’ expectations of $5.24 million. C4 Therapeutics had a negative return on equity of 53.91% and a negative net margin of 325.88%. On average, equities analysts anticipate that C4 Therapeutics, Inc. will post -1.52 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen downgraded shares of C4 Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 9th.

C4 Therapeutics Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.